Journey Medical Corporation
DERM
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $216.3M
$7.86
▼ -0.51%
P/E
-34.79
Mkt Cap
$216.3M
52-Wk Range
$4.31–$9.56
52-Week Range
$4.31 - $9.56
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established portfolio of FDA-approved dermatological medications with proven efficacy
- Diversified product mix combining high-margin branded drugs with stable generic revenue
- Specialized focus and expertise in dermatology market with deep healthcare provider relationships
- Qbrexza's unique market position as a medicated cloth towelette for hyperhidrosis treatment
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expanding market penetration for Qbrexza in the hyperhidrosis treatment market
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+31.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DERM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.01 vs -$0.02 consensus (+55.6% surprise). Revenue of $18.5M vs $18.4M expected (+0.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+55.6%
Revenue trend · last 8Q
—
-11%
+1%
+1%
+21%
+18%
+21%
+23%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$14.6M
$13.6M
$13.1M
$15.0M
$17.6M
$16.1M
$16.0M
$18.5M
Margins · last 8Q
Gross
0.0%
Operating
2.5%
Profit
-1.7%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 13, 2026
vs Industry
How DERM stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related